Stock GUFICBIO GUFIC BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Gufic Biosciences Limited NSE India S.E.

Equities

GUFICBIO

INE742B01025

Market Closed - NSE India S.E.
Other stock markets
 07:43:52 2024-05-31 EDT 		5-day change 1st Jan Change
308 INR -1.61% Intraday chart for Gufic Biosciences Limited -10.48% -2.67%
05-30 Transcript : Gufic Biosciences Limited, Q4 2024 Earnings Call, May 30, 2024
05-29 Gufic Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Gufic Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024
CI
Gufic Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
CI
Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24
CI
Gufic Biosciences Forms New Wholly-Owned Arm in Dubai
MT
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai
CI
Gufic Biosciences Secures Patent in India
MT
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Gufic Biosciences Gets New Patent in India
MT
Gufic Biosciences Forms New Pharmaceutical Subsidiary
MT
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection
CI
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023
CI
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE
CI
Ex-dividend day for final dividend
FA
Gufic Biosciences Granted Patent for its Invention
MT
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder
MT
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection
CI
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023
CI
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion
MT
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUFICBIO Stock
  4. GUFICBIO Stock
  5. News Gufic Biosciences Limited
  6. Highlights